Item analysis of ADAS-Cog: Effect of baseline cognitive impairment in a clinical AD trial

American Journal of Alzheimer's Disease and other Dementias

Volumn 25, Issue 2, 2010, Pages 119-124

  Sevigny, Jeffrey J ^a   Peng, Yahong ^a   Liu, Lian ^a   Lines, Christopher R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ADAS Cog; Alzheimergs disease assessment scale; Item analysis; Placebo; Randomized controlled clinical trial

Indexed keywords

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL DEMENTIA RATING; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DETERIORATION; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROLOGIC EXAMINATION; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM;

EID: 77749246024     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317509350298     Document Type: Article

References (14)

1. Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimergs disease. Am J Psychiatry. 1984 ; 141 (11). 1356-1364.
2. Zec RF, Landreth ES, Vicari SK, et al. Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1992 ; 6 (2). 89-102.
3. Stern RG, Mohs RC, Davidson M., et al. A longitudinal study of Alzheimergs disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 ; 151 (3). 390-396.
4. Schmeidler J., Mohs RC, Aryan M. Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998 ; 12 (3). 146-151.
5. Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial. Neurology. 2008 ; 71 (21). 1702-1708.
6. Mckhann G., Drachman D., Folstein M., et al. Clinical-Diagnosis of Alzheimers-Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimergs Disease. Neurology. 1984 ; 34: 939-944.
7. Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 ; 43 (11). 2412-2414.
8. Folstein MF, Folstein SE, McHugh PR " Mini-mental stategg. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198.
9. Rosen WG, Terry RD, Fuld PA, Katzman R., Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980 ; 7 (5). 486-488.
10. Cleveland WS, Devlin SJ Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988 ; 83 (403). 596-610.
11. Zec RF, Landreth ES, Vicari SK, et al. Alzheimer Disease Assessment Scale: a subtest analysis. Alzheimer Dis Assoc Disord. 1992 ; 6 (3). 164-181.
12. Amatniek J., Zhu Y., Crivera C., et al. Item response models for Alzheimergs Disease Assessment Scale (ADAS-COG): using placebo and baseline data from clinical trials with galantamine. Abstract presented at 11th Congress of the European Federation of Neurological Societies, August 25-28, 2007; Brussels, Belgium. Eur J Neurol. 2007 ;14(suppl 1): 48. http://www.kenes.com/efns2007 Accessed November 20, 2008.
13. Doraiswamy PM, Kaiser L., Bieber F., et al. The Alzheimergs Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimergs disease. Alzheimer Dis Assoc Disord. 2001 ; 15 (4). 174-183.
14. Irizarry MC, Webb DJ, Bains C., et al. Predictors of placebo group decline in the Alzheimergs disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimergs disease. J Alzheimers Dis. 2008 ; 14 (3). 301-311.